This HTML5 document contains 146 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/
n10http://dx.doi.org/10.2147/

Statements

Subject Item
wd:Q36473604
rdf:type
wikibase:Item
schema:description
article scientific article scientifique (publié 2016) 2016年學術文章 bilimsel makale 2016年學術文章 artykuł naukowy article científic artículu científicu espublizáu en 2016 научни чланак tieteellinen artikkeli artigo científico (publicado na 2016) videnskabelig artikel (udgivet 2016) wetenschappelijk artikel мақолаи илмӣ wissenschaftlicher Artikel 2016年学术文章 artikull shkencor գիտական հոդված مقالة علمية научна статия מאמר מדעי articol științific tudományos cikk 2016年學術文章 mokslinis straipsnis 2016年學術文章 სამეცნიერო სტატია 2016 nî lūn-bûn artigo científico επιστημονικό άρθρο artigo científico (publicado na 2016) наукова стаття, опублікована в січні 2016 научни чланак บทความทางวิทยาศาสตร์ vitenskapelig artikkel artículo científico publicado en 2016 scienca artikolo 2016년 논문 2016年學術文章 2016年の論文 bài báo khoa học 2016年学术文章 سائنسی مضمون مقالهٔ علمی teaduslik artikkel naučni članak vetenskaplig artikel 2016年学术文章 2016年學術文章 scientific article vedecký článok vitskapeleg artikkel articolo scientifico ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2016年学术文章 vědecký článek artikulong pang-agham мақолаи илмӣ 2016年学术文章 научная статья
p:P577
wds:Q36473604-8E00380D-B028-4DDC-A137-4F8FB7B3C71F
wdt:P577
2016-01-13T00:00:00Z
p:P407
wds:Q36473604-DA04A5AA-0B1B-4941-8CDA-5991E3F23A3E
wdt:P407
wd:Q1860
p:P2860
wds:Q36473604-8E10C1E5-E87E-49B6-9E6C-4E09F8ABADDE wds:Q36473604-9AE133F2-E69B-428B-8CA8-FCD19CC75430 wds:Q36473604-74AF1329-84B3-4295-92ED-5FC44579D6C3 wds:Q36473604-8B72E382-E7DA-4D56-B101-DF9A3DE02ED4 wds:Q36473604-BF5B8807-A364-4FAC-B571-4F9D2630DDFE wds:Q36473604-CCBDF2B8-A4D3-42B4-9909-7AB56D776477 wds:Q36473604-CFEF8DF3-37C5-40C9-BB0D-234634EBBB9D wds:Q36473604-17858466-FDBB-4B2D-BE0C-A93178C6C1FD wds:Q36473604-23B45F33-CF05-4F9B-822F-4EEE99992587 wds:Q36473604-2BD57A61-521E-4B32-9A3E-4DF8A8D80D2D wds:Q36473604-617D4792-569D-4BC4-B99B-A309BC50613E wds:Q36473604-61B3879C-D248-4C51-88BF-6510F5F28A0F wds:Q36473604-701689E9-405D-4E2C-B14D-B7708EA23115 wds:Q36473604-52645761-7C9A-4304-965B-0F63E7212EC3 wds:Q36473604-5EFC541B-0F6B-4870-860C-E2F4AE0A4474 wds:Q36473604-081D2841-1F06-49C7-A3FC-34FEE573E65B wds:Q36473604-143CD967-1D2B-4D53-A656-6639DE7FD73C wds:Q36473604-16E2ED32-598D-49EF-87E1-B3A7EC128294
wdt:P2860
wd:Q35048648 wd:Q82826313 wd:Q37805740 wd:Q41907591 wd:Q24633874 wd:Q34652928 wd:Q39264662 wd:Q82281523 wd:Q80553646 wd:Q37087181 wd:Q43289502 wd:Q34913612 wd:Q29617549 wd:Q83768562 wd:Q85960573 wd:Q37702939 wd:Q39959029 wd:Q42869103
p:P2093
wds:Q36473604-393BAE46-9F6C-4CD8-8794-177C915AA58D wds:Q36473604-72646497-884B-494E-8B51-322743E109DA wds:Q36473604-F5975765-A789-47B8-B5BF-2B1C29262E46 wds:Q36473604-E732FC42-661B-4797-A99E-39CFA5191DCE
wdt:P2093
Sobha Sivaprasad Philip Hykin Martin McKibbin Jackie Napier
rdfs:label
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK.
skos:prefLabel
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK.
schema:name
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK.
p:P50
wds:Q36473604-3C4826E1-E131-411E-8BE7-29D971F1285A wds:Q36473604-A343AAA6-1A3E-4384-AE2B-8AFDE08E2FB9
wdt:P50
wd:Q54263391 wd:Q61256432
p:P1476
wds:Q36473604-4CA9DC0A-D460-47D9-9A32-87EF68E50AC8
wdt:P1476
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK.
p:P304
wds:Q36473604-FB205C1A-817D-47AA-A6A4-69AB200420D3
wdt:P304
87-96
p:P31
wds:Q36473604-61B4D471-36BE-4278-B3A3-E3CB0EFE7B67
wdt:P31
wd:Q13442814
p:P921
wds:Q36473604-37BFDD8A-1B74-49C7-95AC-5354B1A9CF37
wdt:P921
wd:Q27429789
p:P698
wds:Q36473604-BB14BB20-B676-440F-96D2-7D159DE05603
wdtn:P698
n8:26834453
wdt:P698
26834453
p:P1433
wds:Q36473604-0DBF7019-B7D1-4D9F-81FA-5D0CE8EFFF4A
wdt:P1433
wd:Q5133782
p:P478
wds:Q36473604-18452256-8B85-4295-9AFC-6C7581C3A898
wdt:P478
10
p:P356
wds:Q36473604-2F080BD9-0629-440B-A716-F26C1D6824AD
wdtn:P356
n10:OPTH.S92627
wdt:P356
10.2147/OPTH.S92627
p:P275
wds:Q36473604-93e2628b-2b34-4e22-b4d0-cbb1d6d1966a
p:P6216
wds:Q36473604-adc521f0-0674-4576-bd2f-1a02b886d20c
wdt:P275
wd:Q18810331
wdt:P6216
wd:Q50423863
p:P932
wds:Q36473604-55A8F26C-C205-48D2-805D-C1A87D52AAE5
wdt:P932
4716754